Multiple Myeloma Market to Witness Substantial Growth -- Key Trends and Forecasts of Different Reports for the Next Decade
LAS VEGAS, March 18, 2025 /PRNewswire/ -- Multiple myeloma is a type of cancer characterized by the uncontrolled proliferation of clonal plasma cells, which leads to organ dysfunction and, eventually, death. There were more than 33,000 symptomatic incident cases in the US in 2024, and these cases are expected to grow with a moderate CAGR in the forecast period 2025–2034.
The treatment landscape for multiple myeloma is rapidly evolving, particularly with the increasing use of monoclonal antibodies in newly diagnosed patients. DARZALEX has established a strong market position compared to its competitors. Many emerging therapies under evaluation are expected to complement DARZALEX rather than compete directly with it. Johnson & Johnson is actively exploring treatment sequences that combine DARZALEX with TECVAYLI, CARVYKTI, and TALVEY.
SARCLISA, a newly approved CD38 antibody for multiple myeloma, is gaining traction quickly. However, DARZALEX maintains a significant head start. Both drugs are competing in quadruplet regimens for transplant-eligible and ineligible patients, with competition intensifying, particularly among non-transplant-eligible individuals, supported by evidence primarily from studies involving transplant-eligible groups.
DARZALEX, from Johnson & Johnson, and EMPLICITI, from Bristol Myers Squibb and AbbVie, were both introduced in the same month. However, DARZALEX has outperformed EMPLICITI, achieving blockbuster status.
In 2024, the US multiple myeloma market was valued at USD 15 billion. Significant growth is anticipated by 2034, driven by rising incidence rates, expanded indications, earlier adoption of existing therapies, increasing use of innovative treatments—such as CAR-T cell therapies and anti-BCMA—pipeline advancements, and greater investment in research and development.
Discover more about the multiple myeloma market in detail @ Multiple Myeloma Market Report
DelveInsight has expertise in the oncology market, and an experienced team handles the oncology domain proficiently. DelveInsight has recently released a series of epidemiology-based market reports on multiple myeloma including CAR T-Cell Therapy for Multiple Myeloma, Refractory Multiple Myeloma, Relapsing Refractory Multiple Myeloma, and Triple-refractory Multiple Myeloma. These reports include a comprehensive understanding of current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034 segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Additionally, the reports feature an examination of prominent companies working with their lead candidates in different stages of clinical development. Let's dive deep into the market assessment of these reports individually.
CAR T-Cell Therapy for Multiple Myeloma Market
CAR-T cell immunotherapy is emerging as a groundbreaking treatment for multiple myeloma, providing new hope for patients who have exhausted standard treatment options. Currently, only two CAR-T cell therapies are approved for multiple myeloma: ABECMA (idecabtagene vicleucel) from Bristol-Myers Squibb and CARVYKTI (ciltacabtagene autoleucel) from Johnson & Johnson Innovative Medicine. Their approval underscores the potential of CAR-T therapy as a transformative option for multiple myeloma.
A major benefit of CAR-T therapies is their "one-and-done" approach, which requires just a single administration, unlike bispecific antibodies such as TECVAYLI and TALVEY, which require ongoing treatment. While current CAR-T treatments rely on a patient's own T cells (autologous), research is underway to develop allogeneic CAR-T cells sourced from healthy donors. Allogeneic CAR-T therapies could enable off-the-shelf treatments, improving accessibility and reducing costs.
The approval of CAR-T therapies has created new opportunities for companies developing treatments for advanced-stage multiple myeloma (fourth line and beyond). Key players such as Arcellx (Anito-cel), Novartis (PHE885), Bristol-Myers Squibb (BMS-986393), CARsgen Therapeutics (Zevorcabtagene Autoleucel), and Galapagos (GLPG5301), among others, are advancing their CAR-T candidates at various stages of development.
Overall, the CAR-T cell therapy market for multiple myeloma is expected to expand significantly between 2024 and 2034, driven by its strong efficacy and potential for broader use. Collaboration among pharmaceutical companies and research institutions, along with ongoing innovation, is expected to fuel market growth. However, challenges such as manufacturing complexities and pricing may need to be addressed to fully realize its potential.
For a comprehensive view of the CAR T-cell therapy for multiple myeloma market, check out the CAR T-Cell Therapy for Multiple Myeloma Market Assessment
Refractory Multiple Myeloma Market
Refractory multiple myeloma refers to a form of multiple myeloma in which the disease no longer responds to treatment or relapses shortly after initial therapy. Multiple myeloma is a hematologic cancer caused by the proliferation of malignant plasma cells in the bone marrow, leading to bone damage, anemia, renal dysfunction, and immunodeficiency.
Refractory multiple myeloma typically occurs after patients have been treated with standard therapies such as proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), and monoclonal antibodies but fail to achieve a durable response. Patients with refractory multiple myeloma face a poor prognosis, with limited treatment options and shorter overall survival compared to newly diagnosed or relapsed cases. The complexity of refractory multiple myeloma stems from the disease's ability to develop resistance to multiple therapeutic classes, driving the need for novel treatment strategies.
Several therapies have been approved for treating refractory multiple myeloma, including monoclonal antibodies like DARZALEX (Johnson & Johnson) and SARCLISA (Sanofi), proteasome inhibitors like KYPROLIS (Amgen) and VELCADE (Takeda), and IMiDs like REVLIMID (Bristol Myers Squibb) and POMALYST (Bristol Myers Squibb).
The introduction of CAR-T therapies, such as ABECMA (Bristol Myers Squibb and bluebird bio) and CARVYKTI (Johnson & Johnson and Legend Biotech), has transformed the refractory multiple myeloma landscape by offering targeted, patient-specific treatments. Additionally, bispecific T-cell engagers (BiTEs) like TECVAYLI (Johnson & Johnson) and ADCs like BLENREP (GlaxoSmithKline) have emerged as promising therapies for refractory multiple myeloma.
The refractory multiple myeloma market is growing rapidly, driven by increasing incidence rates, longer survival due to improved treatment options, and the rising number of patients progressing to refractory disease. The market is highly competitive, with major players including Johnson & Johnson, Bristol Myers Squibb, Amgen, Sanofi, and Takeda vying for market share.
The growing adoption of CAR-T and BiTE therapies, combined with ongoing clinical trials investigating next-generation agents targeting BCMA, GPRC5D, and FcRH5, is expected to drive significant growth. However, high treatment costs, manufacturing complexity, and reimbursement challenges remain key barriers to widespread adoption. The introduction of novel modalities such as off-the-shelf CAR-T therapies and targeted ADCs is anticipated to further reshape the competitive landscape in the coming years.
Discover more about refractory multiple myeloma drugs in development @ Refractory Multiple Myeloma Clinical Trials
Relapsing Refractory Multiple Myeloma Market
Relapsing refractory multiple myeloma (RRMM) refers to a stage of multiple myeloma where the disease either returns after a period of remission (relapse) or becomes resistant to existing therapies (refractory). RRMM poses a significant clinical challenge as patients often experience diminishing responses to successive lines of therapy, resulting in poor prognosis and limited treatment options. The high mutation rate and clonal evolution of myeloma cells contribute to treatment resistance, making RRMM a complex disease to manage.
The current market offers a wide array of therapeutic options for treatment, including proteasome inhibitors, immunomodulators, HDAC inhibitors, monoclonal antibodies, chemotherapy, corticosteroids, nuclear export inhibitors, and CAR-T cell therapy across various treatment stages. Disease-targeted treatments typically involve medications such as targeted therapies and/or chemotherapy, with or without steroids. Bone marrow or stem cell transplantation may also be considered. Additionally, radiation therapy and surgery are employed in specific cases.
Several promising drugs are in the pipeline, including Mezigdomide (Bristol Myers Squibb/Celgene), Linvoseltamab (Regeneron Pharmaceuticals), BGB-11417 (BeiGene), PHE885 (Novartis), Iberdomide (Bristol-Myers Squibb/Celgene), and CART-ddBCMA (Arcellx), among others.
The RRMM market is experiencing rapid growth driven by the increasing incidence of multiple myeloma, the need for more effective treatments for relapsed and refractory cases, and the introduction of novel mechanisms of action. Challenges such as high treatment costs, access to CAR-T therapies, and the development of resistance to current treatments are influencing market dynamics. However, the pipeline remains robust, with a focus on next-generation CAR-T therapies, bispecific antibodies, and targeted small molecules, indicating a competitive and evolving landscape.
To gain a deeper understanding of the RRMM market, be sure to explore the Relapsing Refractory Multiple Myeloma Market Outlook
Triple-refractory Multiple Myeloma Market
Triple-refractory multiple myeloma (TRMM) is a challenging form of the disease characterized by resistance to at least three different classes of therapies, including immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies. Patients with TRMM often face poor prognoses and limited treatment options, necessitating the development of novel therapeutic strategies. Recent advances in understanding the disease's biology have led to innovative approaches, including targeted therapies and combination regimens.
The landscape of treatment for triple-refractory multiple myeloma is rapidly evolving, with a focus on innovative therapies that address the unique challenges posed by this aggressive disease. TRMM patients have exhausted standard treatment options, making them reliant on emerging therapies that target specific pathways involved in myeloma progression. The introduction of CAR-T therapies, such as idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), has shown promising results in clinical trials, offering hope for improved outcomes in this difficult-to-treat population.
Currently, several drugs have received approval for treating relapsed or refractory multiple myeloma, including pomalidomide and selinexor, which are used in various combinations to enhance efficacy. Companies like Amgen, Bristol-Myers Squibb, and Karyopharm Therapeutics are actively involved in developing new therapies for TRMM, focusing on novel agents such as BCMA-targeted treatments.
The market dynamics are shaped by the increasing prevalence of multiple myeloma, increasing demand for effective treatments, the high cost of novel therapies, and the ongoing need for clinical trials to validate new treatment regimens. As research continues, the focus remains on improving patient outcomes and quality of life through personalized treatment strategies.
Explore in-depth for a comprehensive understanding of the Triple-refractory Multiple Myeloma Clinical Trials
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur info@delveinsight.com +14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/multiple-myeloma-market-to-witness-substantial-growth--key-trends-and-forecasts-of-different-reports-for-the-next-decade--delveinsight-302404042.html
SOURCE DelveInsight Business Research, LLP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
InventHelp Inventor Develops New Potty Training Accessory (SGM-538)
PITTSBURGH, Aug. 15, 2025 /PRNewswire/ -- "I wanted to create a product that would make potty training a less stressful and more positive experience for parents and children," said an inventor, from New Palestine, Ind., "so I invented THE POTTY PARTNER. My design could help provide a positive transition from diapers to toilet use, and it could allow for successful training in a shorter time or at an earlier age." The patent-pending invention provides an effective accessory for toilet training a child. In doing so, it would teach young children how to use the toilet in a positive and non-stressful manner. It also could help with safety issues. As a result, it could help simplify the task of toilet training. The invention features a durable and novel design that is easy to attach, use, and clean so it is ideal for parents with infants and children ages 3 and younger. Additionally, a prototype model and technical drawings are available upon request. The original design was submitted to the Indianapolis sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 24-SGM-538, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at View original content to download multimedia: SOURCE InventHelp Sign in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Epigenetics Market worth US$4.29 billion in 2030 with 13.9% CAGR
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- The global Epigenetics Market, valued at US$2.03 billion in 2024, stood at US$2.24 billion in 2025 and is projected to advance at a resilient CAGR of 13.9% from 2025 to 2030, culminating in a forecasted valuation of US$4.29 billion by the end of the period. The major factors driving the growth in the flow cytometry market include advancements in technology, increasing adoption of flow cytometry products in clinical diagnostics, rising prevalence of chronic diseases, growing biopharmaceutical R&D, and the need for precision medicine. The significant rise in oncology research has increased the demand for flow cytometry products and services. Additionally, the integration of AI and machine learning is enhancing data analysis capabilities, further fueling market growth. Download PDF Brochure: Browse in-depth TOC on "Epigenetics Market" 365 - Tables45 - Figures353 - Pages By offering, the global epigenetics market is segmented into various categories, including kits and reagents, enzymes, instruments and accessories, software, and services. Within the kits and reagents category, there are sub-segments such as antibodies, chip-sequencing kits and reagents, bisulfite conversion kits and reagents, whole-genome amplification kits and reagents, 5-HMC and 5-MC analysis kits and reagents, histones, as well as other kits and reagents. In 2024, the Antibodies segment is projected to command the largest market share. This is attributed to the increasing reliance on antibodies for the detection, identification, and modification of proteins, along with their essential function in monitoring cellular regulation and gene expression. Consequently, the growth of the antibodies segment is expected to accelerate throughout the forecast period due to these advancements. By Method, the epigenetics market segmentation by methodology includes DNA methylation, histone modifications, and additional approaches such as non-coding RNA interactions and chromatin remodeling. The DNA methylation segment is projected to exhibit a robust compound annual growth rate (CAGR) throughout the forecast period, primarily driven by its proven effectiveness in oncology research applications. By geography, The Asia Pacific region is projected to experience the most rapid growth within the epigenetics market. This expansion is driven by the increasing global footprint of local companies through strategic alliances and collaborations, alongside continuous enhancements in healthcare infrastructure in emerging economies. Moreover, there is a heightened emphasis on advancing capabilities in Next-Generation Sequencing (NGS), which is further propelling market development in the region. Request Sample Pages : Key players in the epigenetics market include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Illumina, Inc. (US), PacBio (US), Danaher (US), Active Motif, Inc. (US), Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Revvity (US), QIAGEN (Germany), among others. Illumina Inc (US): In 2024, Illumina, Inc. maintained a preeminent position in the genomics market, capitalizing on a well-established customer base that includes leading pharmaceutical and biotechnology companies, genomic research institutions, and various government laboratories and hospitals. The firm possesses a dominant market share in the next-generation sequencing (NGS) domain, which affords it a competitive edge when exploring adjacent sectors, such as epigenetic sequencing. A notable move in this direction occurred in June 2025, when Illumina announced its acquisition of SomaLogic. This strategic acquisition is poised to bolster Illumina's footprint in the burgeoning epigenetics market and further its multiomics strategy, integrating diverse biological data for enhanced insights into genomics, transcriptomics, proteomics, and epigenomics. Thermofisher Scientific Inc. (US) Thermo Fisher Scientific Inc. (US) stands out as a prominent player in the epigenetics market in 2024, driven by a robust and diversified product portfolio, an extensive global footprint, and a strategic focus on both organic and inorganic growth initiatives. Notably, in July 2025, the company secured US Food and Drug Administration (FDA) approval for the Oncomine Dx Express Test, utilizing the Ion Torrent Genexus Dx Integrated Sequencer as an in vitro diagnostic (IVD) assay designed for companion diagnostics (CDx) in tumor profiling applications. Thermo Fisher demonstrates a strong commitment to research and development, channeling significant resources into innovation to address the dynamic needs of its clientele. Their comprehensive global distribution network enhances accessibility and customer support, facilitating the delivery of advanced and reliable epigenetics solutions. This multifaceted strategic approach solidifies Thermo Fisher's position as a leading provider in the epigenetics landscape. For more information, Inquire Now! Related Reports: Research Antibodies & Reagents Market Genomics Market Next Generation Sequencing Market PCR Technologies Market Digital PCR and qPCR Market Get access to the latest updates on Epigenetics Companies and Epigenetics Market Size About MarketsandMarkets™: MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter, LinkedIn and Facebook. Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC.1615 South Congress 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Road Safety Market worth $12.39 billion by 2030
DELRAY BEACH, Fla., Aug. 15, 2025 /PRNewswire/ -- According to MarketsandMarkets™, the global Road Safety Market size is projected to reach USD 12.39 billion by 2030 from USD 6.69 billion in 2025, at a CAGR of 13.1% from 2025 to 2030. Browse 386 market data Tables and 62 Figures spread through 379 Pages and in-depth TOC on "Road Safety Market - Forecast to 2030" Scope of the Report Market Size Available for Years: 2020–2030 2025 Market Size: USD 6.69 billion 2030 Projected Market Size: USD 12.39 billion CAGR (2025–2030): 13.1% Segments covered: Offering, Deployment Model, Data Type, Enforcement Type, Application, End User, and Region. Region Highlight: North America is expected to account for the largest market share during the forecast period. Download PDF Brochure @ Increasing government regulations for road safety compliance, rising investments in smart transportation infrastructure, and the growing need to reduce traffic fatalities are driving the growth of the Road Safety Market. Deployment of intelligent traffic systems (ITS), speed enforcement cameras, and advanced surveillance solutions further supports market expansion. Advancements in sensor technologies and AI-based traffic monitoring solutions contribute to enhanced incident detection and prevention. These factors help authorities manage traffic efficiently, enforce regulations, and improve overall public safety. Video & image data type segment will register the largest market share during the forecast period The video and image data type segment is projected to hold the largest market share in road safety due to its critical role in real-time traffic monitoring, incident detection, and law enforcement. High-definition cameras and image analytics enable accurate identification of violations such as speeding and red-light jumping. Growing adoption of AI-powered video analytics for automated license plate recognition, vehicle classification, and pedestrian detection further strengthens the segment's dominance in enhancing road safety and traffic management. Request Sample Pages@ Driver behavior monitoring application is poised for the fastest growth rate during the forecast period The driver behavior monitoring application is expected to grow at the fastest rate in the Road Safety Market due to increasing focus on reducing human error-related accidents. Fleet operators and transportation authorities are adopting driver monitoring systems to track fatigue, distraction, and risky driving patterns in real-time. Integration of AI, telematics, and IoT technologies allows proactive alerts and corrective actions, improving driver accountability and road safety outcomes, thereby driving rapid adoption of this application across sectors. North America is expected to account for the largest market share during the forecast period North America is projected to hold the largest market share in the Road Safety Market due to strong government regulations, significant investments in smart transportation infrastructure, and widespread adoption of advanced traffic management systems. The presence of leading technology providers, early adoption of AI-powered surveillance solutions, and active implementation of intelligent transportation systems (ITS) further drive regional growth. Additionally, initiatives aimed at reducing traffic fatalities and improving public safety enhance demand for road safety solutions across the region. Inquire Before Buying@ Top Key Companies in Road Safety Market: The major players in the Road Safety Market include Siemens (Germany), Motorola Solutions (US), Jenoptik (Germany), Kapsch TrafficCom (Austria), Sensys Gatso Group (Sweden), Verra Mobility (US), Teledyne FLIR (US), IDEMIA (France), Vitronic (Germany), and SWARCO (Austria). Browse Adjacent Markets: Physical Safety Market Research Reports & Consulting Related Reports: Next Generation Emergency Response System Market - Global Forecast to 2028 Public Safety and Security Market- Global Forecast to 2029 Edge Computing Market - Global Forecast to 2030 Data Center Solutions Market - Global Forecast to 2030 AI Assistant Market - Global Forecast to 2030 Get access to the latest updates on Road Safety Companies and Road Safety Industry About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. To find out more, visit or follow us on Twitter , LinkedIn and Facebook . Contact:Mr. Rohan SalgarkarMarketsandMarkets™ INC. 1615 South Congress Ave. Suite 103, Delray Beach, FL 33445USA: +1-888-600-6441Email: sales@ Our Website: Logo: View original content: SOURCE MarketsandMarkets Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
